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Themitochondrial chaperonin Hsp60 is a ubiquitous molecule withmultiple roles, constitutively expressed
and inducible by oxidative stress. In the brain, Hsp60 is widely distributed and has been implicated in
neurological disorders, including epilepsy. A role for mitochondria and oxidative stress has been proposed
in epileptogenesis of temporal lobe epilepsy (TLE). Here, we investigated the involvement of Hsp60 in TLE
using animal and human samples. Hsp60 immunoreactivity in the hippocampus, measured by Western
blotting and immunohistochemistry, was increased in a rat model of TLE. Hsp60 was also increased in the
hippocampal dentate gyrus neurons somata and neuropil and hippocampus proper (CA3, CA1) of the
epileptic rats.We also determined the circulating levels ofHsp60 in epileptic animals andTLE patients using
ELISA. The epileptic rats showed circulating levels of Hsp60 higher than controls. Likewise, plasma
post-seizure Hsp60 levels in patients were higher than before the seizure and those of controls. These results
demonstrate thatHsp60 is increased in both animals and patients with TLE in affected tissues, and in plasma
in response to epileptic seizures, and point to it as biomarker of hippocampal stress potentially useful for
diagnosis and patient management.
E
pilepsy is one of the most common chronic neurologic disorders affecting approximately 1% of the world
population1,2. This disease has deleterious effects on the quality of life affecting independent living, edu-
cation, employment, mobility, and personal relationships. Epilepsy is characterized by spontaneous recur-
rent seizures (SRSs) caused by abnormal, synchronized, high frequency neuronal discharges3. Neuronal
excitability can be affected by mitochondrial alterations such as depletion of ATP, generation of ROS, elevated
oxidative stress, disruption of Ca21 homeostasis, dysregulation of excitotoxicity, and alterations in biosynthesis
and metabolism of neurotransmitters4.
The most common type of epilepsy in adult humans is temporal lobe epilepsy (TLE), characterized by a
progressive development of SRSs from temporal lobe foci and unique morphological alteration in the hippocam-
pus2,5. Usually, TLE is initiated by a first hit, such as head trauma or stroke, brain infection, or febrile seizures that
induce a status epilepticus (SE). The period between the initial injury and the occurrence of the first epileptic
seizure is named epileptogenesis. This is a clinically silent period of 5–10 years in which a cascade of neurobio-
logical events, and histological and biochemical changes occur3. The chronic process that follows the initial insult
involves neuronal activation with intracellular calcium accumulation, and activation of gene expression and
protein synthesis. Inflammation develops at the site of injury, involving glial and endothelial cells6. At the later
stage of epileptogenesis, sprouting of new axons and synapses, and angiogenesis occur changing the nerve tissue
microarchitecture7. Recently, experimental and clinical data have also demonstrated a causative role played by
inflammation in TLE comorbidities such us mood disorders and cognitive impairments8. Therefore, biochemical
measurements of inflammatory mediators in blood and serum might reflect the degree and extent of brain
inflammation and, thus, provide powerful tools for diagnostic, prognostic and therapeutic purposes for example
in TLE due to hippocampal sclerosis patients8.
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Among the neuroinflammatory mediators, heat shock proteins
(Hsps) can be considered promising candidates as useful biomarkers
in CNS disorders including TLE9. Many Hsps are molecular chaper-
ones constitutively expressed under normal temperature that have
indispensable functions in the life cycle of proteins, and play a role in
protecting cells from deleterious stressors. Molecular chaperones are
able to inhibit the aggregation of partially denatured proteins and
refold them in order to maintain protein homeostasis and tissue
physiology. In this regard, these proteins offer a promising alterna-
tive for protection against stressors, and as therapeutic agents for
diseases caused by protein misfolding10,11. Numerous Hsps are crit-
ical regulators in normal neural physiology as well as in cell stress
responses12,13. Emerging evidence involves Hsps in synaptic trans-
mission, autophagy, stress response related to the endoplasmic
reticulum, protein kinase and cell death signaling. These functions,
together with the classical functions of molecular chaperones, indi-
cate that manipulation of Hsps may have significant effects on the
fate of cells in neurological injury and disease states13.
One member of the Hsps is Hsp60, a mitochondrial protein con-
stitutively expressed under normal conditions and induced by dif-
ferent types of stressors such as heat shock, oxidative stress, andDNA
damage14. Inside mitochondria, Hsp60 together with Hsp10 consti-
tute a folding machine for the correct folding of other mitochondrial
proteins15,16. In the brain, Hsp60 is endogenously expressed in astro-
cytes, neurons, microglia, oligodendrocytes, and ependymal cells17.
This distribution suggests an active participation of this chaperonin
in many functions of the brain both in normal and pathological
conditions.
Recently, new locations and functions have been found for this
chaperonin, also related to its structural characteristics, describing
Hsp60 as an ubiquitous molecule with multiple roles in health and
disease18,19. Hsp60 can accumulate in the cytosol and plasma mem-
brane, reaching the extracellular space via secretory vesicles18,20. In
the extracellular environment, Hsp60 can interact with receptors
present on immune cells21,22 and reach the bloodstream acting as a
‘‘chaperokine’’ at distant sites23. Hsp60 participates in a number of
inflammatory and autoimmune processes24,25, including some affect-
ing the nervous system, such as multiple sclerosis and myasthenia
gravis10,26. In view of the information available about the various roles
of Hsp60 in the central nervous system, in the present study we firstly
investigated the expression and distribution of Hsp60 in the rat
hippocampus. We used a model of partial complex (limbic) seizures,
based on the phenomenon of maximal dentate activation (MDA)
recorded in the dentate gyrus (DG), which is induced by repetitive
electrical stimulation of the perforant path (PP) in anesthetized
rats27–29. The analysis was conducted using Western blotting and
immunohistochemistry on hippocampal tissue samples. The levels
of Hsp60 in the blood of epileptic rats were determined using ELISA.
The same technique was used to assay the levels of Hsp60 in the
blood of patients before and after the occurrence of a temporal lobe
seizure.
Results
Maximal dentate activation (MDA). MDA was electrophysiolo-
gically characterized by (1) the onset of large-amplitude (i.e., 20–
40 mV) population spikes (PSs) fired in bursts, and (2) a rapid
increase in amplitude of DG PS28,29. Stimulus trains of 10 s (pulses
of 0.3 ms duration, at 20 Hz) were delivered through the PP
electrode at an initial intensity of 200 mA. If MDA was not elicited,
the stimulus intensity was increased in steps of 50 mA and redeli-
vered every 2.5 min until MDA was induced. Usually, threshold was
reached at 350 6 100 mA, and stimulus intensity was further
increased by 100 mA. For each stimulus, the duration of MDA,
time to onset and after discharge (AD) were measured as shown in
Fig. 1A. Time to onset and duration of MDA were measured as
repeated seizure-inducing trains and were delivered every 10 min
for the next 4 h (total of 24 stimulus trains). As shown in Fig. 1A,
the latency to MDA onset was measured from stimulus onset to the
point of PS appearance with half of the maximal amplitude. The
duration of MDA increased and the time to onset gradually
decreased. The measured durations of MDA and time to onset
(Fig. 1B) were ‘normalized’ by subtracting their duration in
response to the first stimulus from the duration in response to
each subsequent stimulus train. Thus, for individual stimulus
trains after the first, a change in duration (or time to onset) was
calculated. In this way, data from separate animals were averaged.
There was a gradual increase in the change of duration of MDA over
the first 14 stimuli (Fig. 1A,B) which then became quite variable
reaching 24.5 6 2.4 s (n 5 9) after the 24th stimulus. There was
also a gradual decrease in the time of onset to 22.2 6 0.3 s (at the
8th stimulus) and then a plateau (Fig. 1A,C).
Effect of MDA on Hsp60 levels in the hippocampus measured by
Western blotting. Hsp60 was quantified in lysates of the hippo-
campi, derived from control rats (Ctrl, n 5 6), rats with the
electrodes positioned in hippocampus and left in place for a total
of 4 h without stimulation (shams, n 5 5) andMDA-stimulated rats
(n5 9) (Fig. 2A,B). Hsp60 levels were normalized to beta actin levels.
Hsp60 was increased up to 1.5 fold of the basal level for MDAI (right
hippocampus ipsilateral to the PP stimulation) and for MDAC (left
hippocampus contralateral to the PP stimulation) (p # 0.05 vs Ctrl
and sham animals) (Fig. 2B). The difference between Ctrl and sham
animals as well as the difference betweenMDAI andMDACwere not
statistically significant (Fig. 2A,B).
Hsp60 levels in the dentate gyrus and hippocampus proper follow-
ing MDA. To determine the localization of Hsp60, immunostaining
was performed. In Ctrl animals (Fig. 3) as well as in sham animals
(not shown) Hsp60 was detected in all the hippocampal sectors such
as DG, CA3 and CA1 (Fig. 3A–C). Hsp60 immunoreactivity was
localized in the DG granule cells (Fig. 3A), and in CA3 (Fig. 3B)
and CA1 pyramidal cells (Fig. 3C). There was also a diffuse neuro-
pilar labeling of undetermined association with specific elements. In
MDA-stimulated rats Hsp60 immunoreactivity was increased in the
DG (Fig. 3D,G), CA3 (Fig. 3E,H), and CA1 (Fig. 3F,I), both inMDAI
and MDAC compared to Ctrl rats, along the strata of these
hippocampal sectors. This Hsp60 increase was observed on neuron
somata and neuropil. The Hsp60 immunoreactivity increase in
MDA-rats compered to Ctrl and sham rats was statistically
significant (Fig 4, p # 0.001).
Hsp60 levels in the plasma ofMDA-stimulated rats.The difference
between plasmatic levels of Hsp60 in MDA-stimulated rats com-
pared to the plasmatic levels in shams (p # 0.05) and Ctrls (p #
0.05) was statistically significant. No significant differences between
Hsp60 plasmatic levels in sham rats compared to the Ctrls were
revealed. Hsp60 levels in MDA-stimulated rats (n 5 9) ranged
between 5.23 ng/ml and 26.88 ng/ml (mean: 12.76 6 8.28 ng/ml)
and in sham rats (n 5 5) ranged between 3.95 ng/ml and 9.79 ng/ml
(mean: 6.52 6 2.51 ng/ml). Hsp60 plasmatic levels in Ctrl rats (n 5
6) ranged between 3.40 ng/ml and 6.76 ng/ml (mean: 5.11 6
1.36 ng/ml) (Fig. 5A). Moreover, there was a negative correlation
between the onset of the first MDA induced by electrical activation
of the PP and the plasma Hsp60 levels measured at the end of the
experiment (Pearson’s r 5 20.721, p # 0.05) (Fig. 5B). No other
correlations were revealed between Hsp60 and MDA parameters
(not shown).
Hsp60 levels in the plasma of subjects with epilepsy.The difference
between plasmatic levels of Hsp60 in patients after epileptic
seizure (n 5 10), compared to levels in the same subjects before
the epileptic seizure was statistically significant (p # 0.05), as well
as when it was compared to Ctrls (p # 0.05). Hsp60 levels ranged
www.nature.com/scientificreports
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between 3.22 ng/ml and 6.41 ng/ml (mean: 4.74 6 1.22 ng/ml) in
the plasma of patients before the attack and between 5.72 ng/ml
and 31.72 ng/ml (mean: 11.81 6 5.73 ng/ml) in plasma of
patients after the attack. By contrast, there was no difference
between Hsp60 plasmatic levels in patients before the attack and
levels in Ctrl subjects. Hsp60 plasmatic levels in Ctrl subjects (n 5
10) ranged between 4.01 ng/ml and 9.39 ng/ml (mean: 5.34 6
2.03 ng/ml) (Fig. 6).
Figure 1 | Maximal dentate activation (MDA). Representative electrophysiological recording of MDA and after discharge (AD) recorded in alternating
current (AC)mode in the dentate gyrus of the hippocampus induced by 10 s electrical stimulation at 20 Hz in a urethane-anesthetized rat. (A) The Time
to onset is defined by the time that occurs from the beginning of the stimulus train to the midpoint of the maximum amplitude of the PSs. Note the
increase in MDA and AD between the first and the 14th stimulus. (B) Duration and (C) time to onset of MDA, which were measured for each stimulus
train. These values were then normalized, averaged and plotted (6 SEM) against stimulus number. Each solid square represents the mean value from 9
animals.
www.nature.com/scientificreports
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Discussion
To fully appreciate the physiopathological and clinical (practical)
significance of the observations reported, the following topics, from
the general to the specific, must be discussed: (i) the impact of stress
on Hsps in the CNS; (ii) the association between Hsp60 in the CNS
and TLE; (iii) the association of TLE and Hsp60 in mitochondria
with oxidative stress; and (iv) the association of Hsp60 beyond mito-
chondria with TLE.
The impact of stress on Hsps in the CNS has been examined for
years, and it has been suggested that stress induces elevation of Hsps
as amechanism of cellular defense to injury10. However, existing data
also suggest the involvement of Hsps in neuronal damage caused by
SE, although their role in neurodegeneration during epilepsy still
remains uncertain9,30–33. In animal models of epilepsy, increased
Hsp70 expression during acute34 and chronic phases35 has been
documented. In TLE patients, complete remission of mesial TLE
seizures postsurgery was associated with decreasedHsp70 expression
inCA4 and subiculum and decreasedHsp90 expression in the granu-
lar layer36. Higher Hsp70 serum levels in patients with TLE as com-
pared to controls were observed, and were predictive of higher
Figure 2 | Hsp60 levels in the hippocampus of control andMDA-stimulated rats. (A) Representative cropped blots for Hsp60 in control (Ctrl), without
stimulation (sham), right ipsilateral (MDAI) and in contralateral (MDAC) hippocampus to the stimulation of the perforant pathway (PP). The gels were
run under the same experimental conditions and b-actin was used as an internal control. (B) Ratio Hsp60 levels/b-actin levels as a reflection of Hsp60
increase (mean 6 SD). One-way ANOVA for repeated measurements followed by Bonferroni post-hoc test; Dp # 0.05 vs. Ctrl and Sham.
Figure 3 | Levels and preferential localization of Hsp60 in control non-stimulated rats (Ctrls) and in MDA-stimulated rats. (A–C) Immunohistochemical
staining for Hsp60 in the hippocampus of control non-stimulated rats. (D–F) Representative microphotographs of Hsp60 levels in the hippocampus of
MDA-stimulated rats, ipsilateral to the perforant pathway (PP) stimulation (MDAI). (G–I) Representative microphotographs of Hsp60 levels in the
hippocampus of MDA-stimulated rats, contralateral to the PP stimulation (MDAC). As shown in the microphotographs (A–C) and in the relative insets,
in Ctrl animals Hsp60 was detected in all the hippocampal sectors. In the dentate gyrus (DG), Hsp60 immunoreactivity was in the granular cell layer
while in the CA3 sector and CA1 sector was for the most part in the pyramidal cell layer. The illustrative images of MDA-stimulated rats (D–I) and the
relative insets show that Hsp60 immunoreactivity was increased in the DG, CA3 and CA1 sectors both in MDAI and MDAC compared to Ctrl rats. This
Hsp60 increase was observed on neuron somata and neuropil. Bar 5 100 mm.
www.nature.com/scientificreports
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frequencies of seizures in the TLE group9. Data from animal models
showed that Hsp72 increased levels in specific hippocampal neur-
onal subpopulations correlate with limbic seizure intensity and dura-
tion37 and Hsp27 was found to be a highly sensitive and specific
hippocampal marker for full development of pilocarpine-induced
SE38.
In contrast to other Hsps, Hsp60 levels and expression have only
been sporadically studied in animal models of CNS diseases or
neurological patients. Hsp60 was found increased in the brain stem
after subarachnoid hemorrhage, forebrain or focal cerebral ischemia,
and neonatal hypoxia-ischemia in rats13. Hsp60 was found in the
protein aggregates typical of neurodegenerative diseases such as
Parkinson’s disease (PD) and Alzheimer’s disese (AD), in which a
fundamental role is played by oxidative stress and mitochondrial
dysfunction39,40. Physiologically, neural expression of Hsp60 increases
over the course of development, consistent with the changes of
mitochondrial content in the brain17.
The association between Hsp60 in the CNS and TLE, the most
common type of epilepsy in humans, is poorly understood, and our
study is the first aiming at elucidating this important issue. We
investigated tissue levels and distribution of Hsp60 in the MDA
animal model of TLE. This is an electrographic kindling model using
urethane-anaesthetized rats, marker for reverberatory seizure activ-
ity in hippocampal-parahippocampal circuits28–30. The MDA model
has been extensively used to study the phenomenon of epileptogen-
esis and the effects andmechanisms of new anticonvulsant drugs28–30.
In addition, we measured Hsp60 in the blood of epileptic rats, and in
the plasma of patients before and after temporal lobe seizures.
Immunohistochemistry and Western blotting analyses showed that
the levels of Hsp60 were significantly increased in hippocampal neu-
rons of MDA rats when compared to the controls, including sham
treated rats. Surprisingly, a similar increase occurred in both ipsilat-
eral and contralateral hippocampus to the PP stimulation. These data
are in contrast with the observation of a decrease in Hsp60 levels,
assayed by proteomic analysis, in the rat hippocampus after pilocar-
pine treatment5. This difference may be explained because while we
used acute electric kindling (i.e., the MDA model) the other investi-
gators used chemical stimulation (i.e., the pilocarpine model).
Figure 4 | Increase in Hsp60 levels in MDA-stimulated rats.
Representative histograms showing densitometric measurements of the
Hsp60 staining intensity in controls, shams, and MDA-stimulated rats.
Staining intensity was expressed as pixel intensity. Ctrl: Control; Sham:
Animals with the electrodes left in place for the entire experiment without
stimulation; DG: Dentate gyrus; MDAI: ipsilateral to MDA-stimulation;
MDAC: controlateral to MDA-stimulation. *#p# 0.001 vs Ctrl and sham.
Figure 5 | Increase in Hsp60 plasma levels inMDA-stimulated rats. (A) The levels of Hsp60 in plasma ofMDA-stimulated rats are elevated significantly
in comparison with rats without stimulation (sham) and with the controls (Ctrl). Dp# 0.05 vs. Ctrl and sham. Ctrl: Control. (B) Plasma levels of Hsp60
negatively correlate with the onset of the first maximal dentate activation in a model of temporal lobe epilepsy in rats. Pearson correlation analysis was
performed to describe relationships between the onset of the first maximal dentate activation induced by electrical activation of the perforant path
(stimulus duration 0.3 ms, 20 Hz, per 10 sec) and the plasma Hsp60 levels measured at the end of the experiment (24 stimulations every 10 min). An
alpha level of 0.05 was chosen as statistical threshold. The time to onset of the first MDA correlated negatively with serumHsp60 levels (r 5 20.721, p 5
0.0420). The time to onset is defined as time that occurs from the beginning of the stimulus train to the midpoint of the maximal amplitude of the spike
population.
Figure 6 | Increase in Hsp60 plasma levels in patients after epileptic
seizure. The levels of Hsp60 in plasma after the seizure were elevated
significantly in comparison with the pre-seizure levels, which were the
same as those in normal controls. *p # 0.05 vs controls and pre-attack
group. Ctrl: Control.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9434 | DOI: 10.1038/srep09434 5
Moreover, the timing of the collection of the brains was different,
after 4 h in our case instead of 12 and 72 h after the pilocarpine-
induced SE experiments5.
Any investigation of the possible role of Hsp60 in any diseasemust
consider also mitochondria, the canonical residence of the chaper-
onin, and oxidative stress, typically affecting that organelle.
Therefore, the possible association of TLE and Hsp60 in mitochon-
dria with oxidative stress must be discussed in this report. TLEs are a
group of acquired neurological disorders in which the humans and
animals affected experience recurrent epileptic seizures arising from
one or both temporal lobes of the brain41,42. The large quantity of
mitochondria present in the brain makes this tissue particularly vul-
nerable to oxidative stress-induced damage with high degree of oxy-
gen consumption and less antioxidant capacity. Mitochondrial
oxidative stress and dysfunction have been suggested to be contrib-
uting factors to the development of neurological disorders, TLE in
particular, but their precise role (cause or consequence) in epileptic
seizures has not yet been fully characterized41. Mitochondrial dys-
function and oxidative stress are factors that not only occur acutely as
a result of precipitating injuries such as SE, butmay also contribute to
neuronal cell death, epileptogenesis, and chronic epilepsy. Therefore,
Hsp60, a constitutive mitochondrial protein with specific functions
related to mitochondrial protein folding, especially in response to
oxidative stress43, might play an important role in the physiopathol-
ogy of this type of epilepsy. Overexpression of Hsp60 was associated
with increased activity of mitochondrial complex I after 3,4-dihy-
droxy-L-phenylalanine (L-DOPA) administration to rats39. Hsp60
can be induced by mitochondrial DNA depletion14 and this chaper-
onin can interact directly with other mitochondrial proteins such as
aldehyde dehydrogenase 2, ATP synthase, dihydrofolate reductase,
and human carbonicanhydrase II11. Likewise, Hsp60 associates with
pro-caspase 3 favoring cell survival44 and some of these Hsp60 inter-
actors are affected by oxidative stress leading to the metabolic altera-
tions that characterize TLE45. Hsp60 induction could be considered
as a protective mechanism against epileptic seizures as supported by
the observation that a loss of function of Hsp60 leads to an increased
vulnerability to oxidative stress5, which in turn can affect neuronal
excitability and seizure susceptibility41.
It is also pertinent to discuss our findings considering the asso-
ciation of Hsp60 beyond mitochondria with TLE because over the
last few years it has become clear that Hsp60 not only resides and
works in the mitochondria but also elsewhere, in the cytosol, plasma
cell membrane and outside the cell, including the blood stream20,25,46.
For instance, Hsp60 was detected in the culture supernatants in a
cellular Parkinson’s diseasemodel47 and in sera of patients with brain
tumor, in which the chaperonin was secreted via exosomes that
escaped the brain-blood barrier (BBB) and, thus, was endowed with
a potential systemic and distal signaling property48. Since seizures
can induce brain inflammation and BBB breakdown49,50 in both epi-
leptic rats and humans51, we can hypothesize that a similar scenario
leads to appearance of Hsp60 in the blood in TLE. The release from
neural cells might occur in soluble form, possibly via Golgi or
through microvesicles, e.g., exosomes, but this is a field open to
investigation. In our experiments, Hsp60 significantly increased in
the plasma ofMDA stimulated rats and in the plasma of patients after
epileptic seizure. Moreover, we observed a negative correlation
between the onset of the first MDA induced by electrical activation
of the PP and Hsp60 release in the circulation in the animal model of
TLE. It has been suggested that the latency to onset of MDA can be
used as a gauge of seizure threshold27; this finding suggests that the
animals with intrinsic higher hippocampal excitability have higher
levels of plasma Hsp60 after induction of MDA, revealing a possible
role for Hsp60 in the susceptibility to TLE. On the other hand, Hsp60
release induced by MDAs might be a protective strategy from oxid-
ative stress as it occurs for other neurodegenerative diseases such as
AD52. Seizures induce ROS generation, steady-state levels of ROS
increase and oxidative damage arises when the antioxidant system
and repair processes fails. A vicious cycle occurs including chronic
seizures that generate ROS, which increase above manageable levels:
the whole process leading to chronic epilepsy41. Therefore, elevated
Hsp60 in plasma may be considered a stress biomarker, reflecting
neuronal cell damage in the hippocampus, similarly to serum levels
of Hsp709. Nevertheless, we did not observe a positive correlation
between the amount of expression of hippocampal Hsp60 and its
plasma levels in MDA rats and, therefore, sources of plasma Hsp60
other than the affected hippocampus cannot be excluded.
The preceding discussion of our data within the context of
information from other laboratories, unveils a cause-effect line of
associations in time (with reference to seizures) and space (cells
and tissues) between stress, oxidative stress in particular, mitochon-
drial involvement, and Hsp60 in the mitochondria and beyond the
organelle in the pathogenesis of TLE. While the intimate molecular
mechanisms of these associations and of the way they directly cause
signs and symptoms in TLE have still to be elucidated, the data
reported here are useful in at least two directions: a) Hsp60 levels
in affected tissues and the patients’ blood are clearly altered in rela-
tion to seizures. Therefore, it is justified to launch investigations on
the intimate molecular mechanisms of the chaperonin’s participa-
tion in the initiation of epileptogenesis and disease progression and,
by extension, to develop treatments using the chaperonin as thera-
peutic target or agent, depending on whether it is found pathogenic
or cytoprotective, respectively; and b) Hsp60 in blood is a seemingly
reliable diagnostic biomarker. Hence, its clinical practical utility to
follow patient status, including response to treatment, should be
assessed routinely in the evaluation of humans suffering TLE.
Methods
Animal Studies. Maximal dentate activation. Experiments on animals were
performed at the Department of Physiology and Biochemistry Faculty of Medicine
and Surgery, University ofMalta, Msida, Malta. The care and treatment of all animals
were carried out in accordance with the EU Council Directive 86/609/EEC, the
Animals Scientific Procedures Act 1986. All experimental protocols were approved by
the Faculty of Medicine and Surgery Animal Care and Use Committee, University of
Malta. Every necessary effort was made to minimize the animals’ pain and suffering
and to reduce the number of animals used. Experiments were conducted on male
Sprague–Dawley rats weighing ,300 g from the Charles River Laboratories (Calco,
Lecco, Italy). The rats were housed under a 12 h light-dark cycle (lights on at 7:00
a.m.) at a constant temperature (21 6 1uC) and relative humidity (60 6 5%).
Rats were anesthetized by i.p. urethane (Sigma-Aldrich, Dorset, England)
(1.2 g/kg) administration and positioned in a David Kopf stereotaxic frame. Body
temperature was maintained by a heating pad and a temperature controller unit
(Temperature Control Unit HB 101/2, Letica Scientific Instruments, Laguna Niguel,
CA). Field potentials were evoked by stimulating the PP (AP: 28.3 L: 4.8 V: 3.4)53
with a bipolar stimulating electrode (bifilar twisted stainless steel, Stainless SteelWire
AISI316, Advent). The recording electrode (Tungsten LowResistance Electrode, A-M
Systems Inc., Carlsborg, WA) was implanted into the hilus of the DG of the hip-
pocampus (AP: 24.2 L: 2.2 V: 3.6)53. During the surgical procedure, electrodes were
advanced slowly downward until reaching the optimal depth to record PSs. In order
to record the electrical field during implantation and experiment, a NeuroLog
amplifier (Digitimer Ltd, high pass: 0.2 Hz, low pass: 5,000 Hz, gain: 200) was used.
Square-wave pulses of 0.2 ms duration were applied at 1 per minute, using a constant
current stimulator (Digitimer Ltd, model DS3) and a digitally controlled stimulator.
After the optimal depth for recording PS had been reached, control data were
acquired after a 60 min delay to allow the tissue to recover from any trauma due to
electrode implantation. Stimulus intensity was set to evoke 40–50% of the maximum
amplitude of the PS. Recording of PS was performed using the same settings as during
implantation (see above). Responses were digitized by a CED 1401 plus analogue–
digital converter (Cambridge Electronic Design Ltd., Cambridge, UK), stored on a
computer and averaged offline using Signal 1.9 software. Sampling rate was set to
10 kHz. Location of the recording electrode was verified histologically. The same
recording and stimulation procedure were used under sham implantation. Sham
animals had electrodes positioned in the PP andDG, respectively. The electrodes were
than left in place for a total of 4 h without stimulation.
Tissue collection. For immunohistochemistry, Ctrl rats, shams, and MDA-
stimulated rats (n5 9 per group)were transcardially perfused with 0.01 Mphosphate
buffer saline (PBS, pH 7.4), and then with chilled 4% paraformaldehyde. After post-
fixation, the brains were embedded in paraffin and sectioned coronally (5 mm) using a
microtome. For Western blot analysis the hippocampus of each rat was dissected,
homogenized in cold RIPA buffer (0.3 M NaCl, 0.1% SDS, 25 mM HEPES pH 7.5,
www.nature.com/scientificreports
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1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.5 mM DTT, 0.5% sodium
deoxycholate) containing protease inhibitor cocktail (Sigma Aldrich) and stored at
220uC until use. For ELISA tests whole blood samples were collected fromCtrls (n 5
6), shams (n 5 5), and MDA-stimulated rats (n 5 9) in EDTA-treated tubes and
centrifuged for 15 min at 1000 3 g at 4uC within 30 min of collection. The plasma
was removed, and stored in aliquot at 280uC until use.
Western blotting.Western blotting was performed as previously described54. Equal
amounts of proteins (40 mg) were separated on SDS-PAGE and transferred onto a
nitrocellulose membrane (BioRad, Segrate, Italy). After blocking with 5% albumin
bovine serum (Sigma Aldrich), membranes were probed with primary antibodies
(mouse anti-Hsp60 monoclonal antibody, and mouse anti-b actin monoclonal
antibody, Sigma Aldrich, Milan, Italy) diluted at 151,000 overnight at 4uC. Protein
bands were visualized using the enhanced chemiluminescence (ECL) detection
system (GE Healthcare Life Sciences, Milan, Italy), and the data were evaluated and
quantified using ImageJ Free software (NIH, Bethesda, MD). Each experiment was
performed at least three times.
Immunohistochemistry. Brain sections involving the hippocampus were mounted
on tissue slides and deparaffinized. Sections were immersed in 0.3% H2O2 for 5 min
to quench endogenous peroxidase activity, and treated with 10 mM, pH 6.0, 0.05%
Tween 20 tri-sodium citrate at 95uC for 8 min for antigen retrieval. Subsequently,
immunohistochemistry was performed using the Histostain-Pluss IHC detection Kit
(Histostain-plus Kit3rd Gen IHCDetection Kit, Life Technologies, Monza, Italy) and a
primary antibody against human Hsp60 (mouse anti-Hsp60 monoclonal antibody,
Sigma Aldrich, dilution 15400). Appropriate positive and negative controls, were run
concurrently (Fig. S1).
Nuclear counterstaining was done using hematoxylin (DAKO, Carpinteria, CA).
The slides weremountedwith cover slips and images were takenwith a LeicaDM5000
upright microscope (Leica Microsystems, Heidelberg, Germany). ImageJ 1.41 soft-
ware was used to calculate the density of Hsp60-immunoreactive neurons in the DG
and hippocampus proper (CA3, CA1) of Ctrls and MDA-stimulated rats. The den-
sitometric analysis was performed on five fields per hippocampal sector, five sections
per rat and in four rats per group. The objective lens used was 403. The acquired
images (RGB) were converted into grey scale images (32-bit) and inverted. Staining
intensity of neurons was represented by a histogram and expressed as mean of pixel
intensity (PI). The intensity of a pixel was expressed within a given range between a
minimum (zero) and a maximum (255), where 0 corresponds to no positivity (black)
and 255 to maximal positivity (in greyscale black and white, respectively).
Sections stained only with hematoxylin were run concurrently; pixel intensity was
measured and subtracted from the Hsp60 quantification.
Recruitment of patients. The study was carried out in accordance with the EU
Council Directive for the use of human samples in research and approved by the local
ethics committees at the IRCCS ‘‘NEUROMED’’ (Istituto Neurologico
Mediterraneo), Pozzilli (IS), Italy. Patients were recruited at the Epilepsy surgery Unit
of the IRCCS ‘‘NEUROMED’’. All patients gave written informed consent to the
collection of the blood samples and the processing of their personal data for clinical
research purposes. We recruited 10 patients (Female/Male 5 357; age: 23–49 years;
mean age: 36.1 6 9.18 years) affected by drug-resistant TLE evaluated for surgery by
means of a non-invasive diagnostic protocol described in details elsewhere55. Whole
blood samples were collected in EDTA-treated tubes on the day of admission into the
Unit and at 30minutes after the occurrence of a seizure. After a centrifugation at 2,000
3 g for 10 min, plasma was collected, aliquoted, and stored at280uC until use. Blood
samples were collected from 10 age-matched controls (Female/Male 5 357; age: 22–
52 years; mean age: 36.3 6 9.67 years) at the Unit of Internal Medicine of theAzienda
Ospedaliera Universitaria, Policlinico Hospital, Palermo, Italy.
ELISA tests. ELISA tests were performed as previously described25 using a
commercial Hsp60 (human) enzyme immunoassay (EIA) kit (Enzo Life Sciences,
Vinci, Italy) and a commercial EIA kit for Heat Shock 60 kD protein 1, chaperonin
(HSPD1; rat) (Cloud-Clone Corp. Houston, TX). For the samples of human origin,
the Hsp60 standard was diluted in standard diluent to generate a standard curve with
six points, ranging from 3.125 to 100 ng/ml. For samples obtained from animals,
Hsp60 standard was diluted in standard diluent to generate a standard curve with
seven points, ranging from 3.12 to 200 ng/ml. Standard diluent alone was used as a 0
(zero) standard. Then, 100 ml of prepared standards and undiluted plasma was added
in duplicate to wells of the immunoassay plate precoated with mouse monoclonal
antibody specific for Hsp60 and incubated at 23uC for 1 h and at 37uC for 2 h for
human and rat samples, respectively. After diluting the primary and secondary
antibodies according to the manufacturer’s instructions, 100 ml of anti-Hsp60 goat
polyclonal antibody was added to each well and incubated at 23uC for 1 h and at 37uC
for 1 h for human and rat samples, respectively. Subsequently, 100 ml of horse radish
peroxidase conjugate anti-goat IgG was added to the plate and incubated at 23uC for
30 min and at 37uC for 30 min for human and rat samples, respectively, followed by
100 ml of 3,39,5,59-tetramethylbenzidine substrate for 15 min in the dark. Finally,
100 ml of Stop Solution was added, and absorbance was measured at 450 nm with a
microplate photometric reader (DV990BV4, GDV, Milan, Italy). Sample
concentration was calculated by interpolating the sample measurement in the
standard curve. The sensitivity of the human Hsp60 EIA kit was determined to be
3.125 ng/ml. Human Hsp60 EIA kit is specific for Hsp60 and the Hsp60 ELISA has
been certified for the detection of human Hsp60. The sensitivity of the rat Hsp60 EIA
kit was determined to be 1.29 ng/ml and the assay has excellent specificity for
detection of rat Hsp60. All experiments have been conducted according to the
principles expressed in the last updated Declaration of Helsinki.
Statistical analyses. Statistical analyses were performed using statistical software
package GraphPad Prism4 (San Diego, CA). The data obtained were compared by the
One-way ANOVA analysis of variance using Bonferroni post-hoc multiple
comparisons. The data were expressed as means 6 SD. Statistical significance was
determined at the level of p# 0.05. Pearson’s correlation analysis was performed to
describe relationships between the different parameters of MDA and the serum
HSP60 levels measured at the end of the experiment (24 stimulations every 10 min).
An alpha level of 0.05 was chosen as statistical threshold.
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